![]() They demonstrate that removing beta-amyloid plaques, one of the hallmarks of Alzheimer’s, from the brain results in a reduction in clinical decline with benefits to both cognition and function in people living with the disease. These therapies address the underlying biology of Alzheimer’s and slow disease progression. Another treatment, aducanumab (Aduhelm®), had previously received accelerated approval. Food and Drug Administration for the treatment of early Alzheimer's disease. Lecanemab (Leqembi®) has received traditional approval by the U.S. If the workup doesn't create a clear clinical picture, the doctor may recommend neuropsychological testing, which involves a series of written or computerized tests to evaluate specific thinking skills.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |